Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 378

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.

Graus, F, Dalmou, J, Reñé, R, Tora, M, Malats, N, Verschuuren, J J, Cardenal, F, Viñolas, N, Garcia del Muro, J, Vadell, C, Mason, W P, Rosell, R, Posner, J B, Real, F X·1997·Journal of Clinical Oncology

Abstract

PURPOSE: Anti-Hu antibodies (HuAb) recognize antigens expressed by neurons and small-cell lung cancer (SCLC). High titers of HuAb were initially reported in serum from patients with paraneoplastic encephalomyelitis/sensory neuropathy (PEM/SN) and SCLC. Preliminary studies have indicated that some SCLC patients without PEM/SN harbor low titer of HuAb in their serum, and that the SCLC of these patients may grow more indolently. Based on these observations, we conducted a multicenter prospective study of SCLC patients without PEM/SN to determine the incidence and prognostic implications of HuAb. METHODS: Serum samples were collected at diagnosis of SCLC in 196 patients without PEM/SN. HuAb were determined by immunoblot of purified recombinant HuD antigen. RESULTS: HuAb were detected in 32 (16%) of the 196 patients. Of the 170 patients who received treatment for the tumor, 27 (16%) were HuAb positive. HuAb was associated with limited disease stage (59.3% v 38.6%; P = .047), complete response to therapy (55.6% v 19.6%; P < .001), and longer survival (14.9 v 10.2 months; P = .018). In a logistic regression analysis, HuAb status was an independent predictor of complete response induction. The probability of achieving a complete response was more than five times higher in HuAb-positive than in HuAb-negative patients (odds ratio, 5.4; 95% confidence interval, 1.71 to 16.89; P = .004). Cox multivariate analysis indicated that HuAb status was not independently associated with survival. CONCLUSION: The presence of HuAb at diagnosis of SCLC is a strong and independent predictor of complete response to treatment. This feature accounts for the association between HuAb and longer survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.1997.15.8.2866

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 378

Metadata

Authors
Graus, F., Dalmou, J., Reñé, R., Tora, M., Malats, N., Verschuuren, J. J., Cardenal, F., Viñolas, N., Garcia del Muro, J., Vadell, C., Mason, W. P., Rosell, R., Posner, J. B., & Real, F. X.
Venue
Journal of Clinical Oncology
Published
1997-08
Volume
15
Issue
8
Pages
2866-2872
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1856657326
Cited by
378
References
20
FWCI
6.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. https://app.cochat.ai/papers/10.1200/jco.1997.15.8.2866
The paper
Graus, F., Dalmou, J., Reñé, R., Tora, M., Malats, N., Verschuuren, J. J., Cardenal, F., Viñolas, N., Garcia del Muro, J., Vadell, C., Mason, W. P., Rosell, R., Posner, J. B., & Real, F. X. (1997). Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1997.15.8.2866

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.